There is a good chance that the millions of people watching this year’s Super Bowl will see a commercial for Xarelto. Xarelto, with a generic name rivaroxaban, is making hundreds of millions of dollars for Beyer and Janssen (a wholly owned Johnson & Johnson subsidiary), and these companies will take…
A recent article from Digital Trends takes a look at the frequently aired Xaretlo commercial and the health issues surrounding the drug. In case you haven’t seen the commercial, which would indicate you do not watch any sporting events, and likely do not watch television at all, it stars Kevin…
Xarelto has come under a lot of fire lately, as thousands of people have developed a deadly internal bleeding disorder after taking the anticoagulant, and more than 60 people have died. The basis of these claims are that the makers of Xarelto, Bayer and Janssen (a division of Johnson &…
With the regular NFL season coming to close and playoffs heating up, there will be more people watching football than at any other point in the season. This will, of course, culminate with Super Bowl 50. During the Super Bowl, many will tune in for the big game and others…
Xarelto is a member of class of drugs known as New Oral Anticoagulants (NOACs). It is an alternative to traditional blood thinners such a Warfarin (Coumadin), which is often prescribed to patients who suffer from a serious medical condition known as atrial fibrillation (Afib). Afib is a medical condition classified…
Xarelto, Pradaxa, and Eliquis are three of four New Oral Anticoagulants (NOACs) that are all fighting with each other and the makers of Warfarin (Coumadin) to become the market leader for medications used for the prevention of serious blood clotting disorders in patients who suffer from a medical condition known…
For several years, Pradaxa, Elliquis, and Xarelto have had the market cornered on sales of New Oral Anticoagulants (NOACs) as treatment for patients who suffer from a serious medical condition known as atrial fibrillation (Afib). NOACs are an entirely new class of drugs designed to replace conventional blood thinners, such…
For decades, Warfarin (Coumadin) has been the gold standard drug for atrial fibrillation (Afib) patients to avoid being at a higher risk for stroke and other potentially deadly medical conditions like a pulmonary embolism (PE). While Warfarin is considered relatively safe, it does require patients to have frequent monitoring by…
Xarelto, Eliquis, Pradaxa, and the newly-marketed Savaysa are all members of a class of drugs known as New Oral Anticoagulants (NOACs). They are all advertised as a safer and easier to use alternative to Warfarin (Coumadin), which has been the long-standing drug prescribed to patients who suffer from an irregular…
Pradaxa is one of the popular drugs that are part of a relatively new class of oral anticoagulants used to treat patients who suffer from a medical condition known as atrial fibrillation (Afib). These news drugs have been designed and marketed as better alternatives to Warfarin (Coumadin), which has been…